leuprolide acetate for depot suspension / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   94 Trials   94 Trials   2090 News 


«12...910111213141516171819...3233»
  • ||||||||||  Erleada (apalutamide) / J&J
    Trial completion date, Trial primary completion date:  c15-164: AASUR in High Risk Prostate Cancer (clinicaltrials.gov) -  Feb 9, 2022   
    P2,  N=64, Active, not recruiting, 
    Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023
  • ||||||||||  Enrollment change, Trial completion date, Trial primary completion date:  Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis (clinicaltrials.gov) -  Feb 9, 2022   
    P4,  N=300, Recruiting, 
    Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023 N=150 --> 300 | Trial completion date: Feb 2020 --> Feb 2022 | Trial primary completion date: Jan 2019 --> Jan 2022
  • ||||||||||  progesterone / Generic mfg., leuprorelin depot / Generic mfg.
    Endogenous autoimmune progesterone dermatitis: successful suppression and desensitization () -  Feb 4, 2022 - Abstract #AAAAI2022AAAAI_1535;    
    The patient underwent biopsy showing neutrophilic dermatosis, equivocal skin testing and positive intramuscular challenge resulting in dermatitis flare, consistent with autoimmune progesterone dermatitis. Initiation of leuprolide injections, followed by progesterone desensitization resulted in improvement of dermatitis and no subsequent flares for several years.
  • ||||||||||  leuprorelin depot / Generic mfg.
    Journal:  Pharmaceutical good manufacturing practice: Leuplin production in Japan identifies major international shortcomings. (Pubmed Central) -  Feb 3, 2022   
    In Japan, the production of Leuplin, a key drug for the treatment of prostate cancer and breast cancer, was temporarily suspended in 2020 by the manufacturer. The incident illustrated several significant failings, namely the lack of uniformity in international GMP (Good Manufacturing Practice) regulations, the lack of mechanisms to resolve disputes between PIC/S (Pharmaceutical Inspection Co-operation Scheme) member countries, and the importance of maintaining a stable supply of safe GMP-compliant essential medicines.
  • ||||||||||  leuprorelin depot / Generic mfg., abiraterone acetate / Generic mfg., docetaxel / Generic mfg.
    Journal, PARP Biomarker:  Recent Advances in the Management of Metastatic Prostate Cancer. (Pubmed Central) -  Feb 1, 2022   
    Recently, lutetium-177-prostate-specific membrane antigen-617 with standard of care treatment has shown to improve overall survival in men with advanced-stage prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. These recent approvals, successes, and the ongoing investigation of multiple novel agents are expected to continue to dramatically improve survival outcomes of men with metastatic prostate cancer in the coming years.
  • ||||||||||  leuprorelin depot / Generic mfg.
    Clinical, Journal:  What is the optimal timing of intracytoplasmic sperm injection (ICSI) after EGG retrieval? A randomized controlled trial. (Pubmed Central) -  Jan 27, 2022   
    In good prognosis couples, we observed no difference in fertilization or blastulation rates based on timing of ICSI within the currently accepted 2- to 6-h window post-retrieval based on a 34-h trigger. The oocyte appears to have a physiological tolerance for fertilization during this window of time, and variability in the timing of ICSI during this window is unlikely to have an impact on cycle outcome.
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring
    Clinical, Journal, Real-world evidence:  Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. (Pubmed Central) -  Jan 13, 2022   
    In this emulation of a clinical trial of men with cardiovascular disease undergoing treatment for prostate cancer, degarelix was not associated with a lower risk of cardiovascular events than leuprolide. Comparison of these data with PRONOUNCE trial results, when published, will help enhance our understanding of the appropriate role of using real-world data to emulate clinical trials.
  • ||||||||||  Orgovyx (relugolix) / Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
    Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study. (In-Person & On Demand | Level 1, West Hall - F1) -  Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_336;    
    P3
    Given the limited size of the subgroup, additional research is warranted in this population. Relugolix, an oral nonpeptide GnRH receptor antagonist, had a faster and more complete recovery of testosterone to normal levels after treatment discontinuation versus leuprolide in a subgroup of men from the phase 3 HERO study.
  • ||||||||||  Nubeqa (darolutamide) / Bayer, Orion Corp
    Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer. (In-Person & On Demand | Level 1, West Hall - N5) -  Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_322;    
    P1, P2
    Prior systemic anticancer treatments taken by more than 1 patient were bicalutamide (n = 10); cyproterone (n = 3); and triptorelin and leuprorelin (n = 2 each). Extended darolutamide treatment > 2 years in this small group of patients with mCRPC was generally well tolerated, with safety and tolerability consistent with that previously reported.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US. (In-Person & On Demand | Level 1, West Hall - B12) -  Jan 5, 2022 - Abstract #ASCOGU2022ASCO_GU_281;    
    With rapidly evolving treatment options in metastatic prostate cancer, these data can help guide estimation of eligible patients for different clinical trials. Further studies are needed to understand the high attrition from 1L to subsequent lines of therapy, the reasons for treatment preference and impact on clinical outcomes with different treatment sequencings.
  • ||||||||||  leuprorelin depot / Generic mfg.
    Journal:  Membrane translocation and activation of GnRH receptor sensitize prostate cancer cells to radiation. (Pubmed Central) -  Jan 5, 2022   
    The aim of this study was to evaluate the effect of radiation on PCa cells pretreated with leuprolide, alone or in combination with IN3, as radiosensitizers...This effect was enhanced by pretreatment with pharmacoperone IN3. Clinical use of IN3 as a radiosensitizer combined with androgen deprivation therapy to improve survival of patients with PCa remains to be evaluated.